Asia Pacific Growth Hormone Market size valued at around USD 661 million in 2020 and is set to observe around 8.6% growth rate between 2021 and 2027. Growing awareness about the growth hormone therapy in Asia Pacific will drive the regional market growth. Moreover, initiatives taken by government organizations for better management of the disease has also impelled the market expansion.

Get more details on this report - Request Free Sample PDF

One of the most common therapy prescribed by doctors for GH deficiency is synthetic growth hormone therapy. Synthetic growth hormone is administered through injection and mostly used in children that are unable to produce enough growth hormone naturally. These children generally have a pituitary disorder, that means their pituitary gland does not produce enough HGH. Growing usage of synthetic growth hormone along with rising healthcare expenditure, and presence of large patient pool in this region will boost the market revenue.

Asia Pacific Market, By Product

The powder product segment size in the Asia Pacific growth hormone market was more than USD 419 million in 2020, due to growing usage of powder form of growth hormone coupled with rising demand for powder form due to the various benefits.

Powder form of growth hormone such as SAIZEN, a lyophilized powder manufactured by Merck Serono is one of the most demanding products in Asia pacific region. Similarly, enhancer product (hGH Booster) is one of the powder forms of GH hormones. These growth hormones, also known as GH secretagogues, are available in the form of pill or powder. They contain amino acids that increase the production of GH in the body. Enhancer product manufacturers claim that they are virtually free of side effects and safe.

Asia Pacific Market, By Application

Get more details on this report - Request Free Sample PDF

Turner syndrome segment is expected to grow at 8.7% CAGR during the forecast timeline. Turner syndrome is a genetic condition that only affects females. It is a chromosomal abnormality leading to the absence of all or one of the sex chromosomes or cause other abnormalities. According to the Australian Paediatric Endocrine Group around 25 to 50 in 100,000 girls born with turner syndrome each year. The factor such as increasing incidence of births associated with turner syndrome in this region will fuel the Asia Pacific growth hormone market growth.

Asia Pacific Market, By Distribution Channel

In 2020, the hospital pharmacy segment revenue was around USD 381.5 million in Asia Pacific growth hormone market. This is attributed to rising demand for advanced treatment and diagnosis of growth hormone deficiency and idiopathic short stature.

Furthermore, increase in purchasing power and access to quality healthcare and pharmaceuticals for low income and middle-class families are also driving the industry size. Hospital pharmacies are located within hospitals allowing easy accessibility to patients and supply time-sensitive medicines for critical care by purchasing directly from drug manufacturers.

Asia Pacific Market, By Country

Japan growth hormone market accounted for USD 164 million revenue in 2020, owing to the rising product approval in this region coupled with growing awareness about the diseases associated with growth hormone deficiency.

For instance, two South Korean companies, Handok Inc., and Genexine Inc. are conducting a Phase II clinical trial study on GX-H9, a recombinant human GH for the treatment of adult and pediatric GH deficiency. Similarly, according to The Pharmaceuticals and Medical Devices Agency (PMDA), till date, the PMDA has approved 27 biosimilars, within the product classes of human growth hormone, erythropoiesis stimulating agent and granulocyte colony-stimulating factor.

Competitive Industry Landscape

Eminent companies operating in the Asia Pacific growth hormone market include Novo Nordisk A/S, Pfizer Inc., Novartis AG, Eli Lily and Company, Merck KGaA, Ipsen S.A., Anhui Anke Biotechnology (Group) Co., Ltd, LG Chem Ltd., Ferring B.V., and Genetech Inc. (Roche Group).